Peptide Profile

SS-31

Elamipretide / MTP-131 / Bendavia

Fda Approved10 sourcesShop SS-31

Overview

Composition

Synthetic, cell-permeable tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) designed to selectively target the inner mitochondrial membrane

Mechanism of Action

Binds reversibly to cardiolipin—a phospholipid critical for mitochondrial structure and electron transport chain function—stabilizing supercomplexes, optimizing ATP production, reducing excessive reactive oxygen species (ROS), and protecting against oxidative damage

Primary Effects

Clinical development focuses on mitochondrial diseases and other disorders linked to cardiolipin instability, impaired ATP production, and oxidative stress.

Discovery & Background

Developed in the early 2000s by researchers, including Dr. Hazel Szeto, at Weill Cornell Medicine, focusing on mitochondria-penetrating peptides to address oxidative stress

Advanced by Stealth BioTherapeutics, emphasizing cardiolipin stabilization as a novel mechanism; early preclinical work highlighted its protective effects in models of ischemia-reperfusion injury, heart failure, and neurodegeneration, leading to clinical development starting in the 2010s; in September 2025, the FDA granted accelerated approval for elamipretide (brand name Forzinity) to improve muscle strength in patients with Barth syndrome (a rare mitochondrial disorder) weighing ≥30 kg

FDA-approved for Barth syndrome (as Forzinity); investigational for most other uses beyond this approval, with ongoing trials in additional mitochondrial and ophthalmic indications

Research Overview

Preclinical models (cells, rodents) demonstrate SS-31's ability to restore mitochondrial respiration, enhance ATP synthesis, reduce ROS, improve mitochondrial morphology, and protect tissues in heart failure, Barth syndrome, primary mitochondrial myopathy, neurodegeneration, and ischemia

01
Human clinical trials (Phase 1–3) evaluated it in primary mitochondrial myopathy (e.g., MMPOWER trials), Barth syndrome (TAZPOWER), heart failure (PROGRESS-HF), dry age-related macular degeneration (ReCLAIM), and other indications
02
Showed improvements in exercise tolerance (e.g., 6-minute walk test), muscle strength, and tolerability
03
While some trials met endpoints (e.g., leading to Barth syndrome approval), others were inconclusive or negative for primary outcomes
04
Remains investigational for most uses beyond Barth syndrome
05
Regenerative, longevity, energy, and recovery claims outside Barth syndrome lack controlled evidence

FDA-approved for Barth syndrome; investigational for most other uses

Safety Considerations

Monitoring

Energy levels
Exercise tolerance (e.g., 6-minute walk test)
Muscle strength
Mitochondrial function markers
Overall vitality

Side Effects

Common

Generally well-tolerated in clinical trials
Headache, nausea, or fatigue have been reported in trial settings
Approved-label safety should be separated from unapproved longevity or recovery claims

Contraindications

Limited long-term data outside approved use (Barth syndrome)
Potential risks (e.g., unknown prolonged effects) are not fully characterized
Remains investigational for most uses beyond FDA approval

Educational Notice

SS-31/elamipretide has FDA accelerated approval for Barth syndrome as Forzinity, but most other uses remain investigational. Human evidence varies by indication, and long-term data outside approved use are limited. Potential risks are not fully characterized for off-label longevity, recovery, or regenerative claims, so clinical decisions require qualified medical oversight.

References